Author
Imperial College LondonORCID 0000-0001-7358-8851Unclaimed ORCID profile · follow to get notified of new preprints
6 papers
Recent·Most cited
Yurui Ma, Evon Poon, Chenchen Jin…·Anke M. Nijhuis
This paper combines RBM39 degradation and SRPK1 inhibition to disrupt RNA splicing in neuroblastoma, showing synergistic anti-cancer effects in cell lines and a mouse model.
Michael Gruet, Yitao Xu, Lijie An…·Hector C. Keun
This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.
Roshni A. de Souza, David Barneda, Donja Karimlou…·Véronique Azuara
The paper identifies a lipid metabolism-induced checkpoint during the exit of naïve pluripotency that ensures genome integrity through telomere regulation.
Jenna Robinson, Gem Flint, Ian Garner…·Marco Di Antonio
This study identifies G-quadruplex structures as regulators of long-range transcriptional reprogramming in drug-resistant ovarian cancer, showing their role in promoting resistance and potential as therapeutic targets.
Simeon D. Draganov, Michael Gruet, Daniel Conole…·Edward W. Tate
The paper introduces a chemical tool, 6Yn-Pro, for identifying intracellular ADP-ribosylated proteins through metabolic labeling and chemical proteomics in HEK293T cells.
Sarah Spear, Olivia Le Saux, Hasan Mirza…·Iain A. McNeish
This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.